IRD

Opus Genetics, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website -
Employees(FY) -
ISIN US67577R1023

Performance

-14.04%

-25.76%

-27.94%

-41.84%

-67.44%

YTD

-66.21%

Profile

Advanced Technical Analysis

Technical Analysis of IRD 2024-11-20

The stock's Moving Average Score of 10 indicates a strong bearish sentiment, while the Oscillators Score of 56 suggests a neutral stance. Overall, the Technical Score of 33 reinforces the bearish outlook, indicating that the stock may face downward pressure in the near term.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of IRD

Stock Rank

Recent News & Updates

2024-11-13 17:40
Opus Genetics reinstated with a Buy at H.C. Wainwright(Yahoo Finance)
2024-11-11 19:00
Opus Genetics Announces Financial Results for Third Quarter 2024 and Provides Corporate Update(Globenewswire)
2024-11-11 18:59
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-10-25 00:00
The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics(Yahoo Finance)
2024-10-23 05:31
Ocuphire Pharma Merges with Opus Genetics, Renamed Opus Genetics(Yahoo Finance)
2024-10-22 04:05
Ocuphire Pharma Announces Acquisition of Opus Genetics(Globenewswire)
2024-09-29 20:00
Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology(Globenewswire)
2024-09-05 08:43
UPDATE Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia(Globenewswire)
2024-09-04 20:00
Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia(Globenewswire)
2024-08-12 20:00
Ocuphire Pharma Announces Financial Results for Second Quarter 2024 and Provides Corporate Update(Globenewswire)
2024-08-07 20:00
Ocuphire Pharma to Present at Two Investor Conferences in August(Globenewswire)
2024-07-09 20:00
Ocuphire Pharma to Highlight APX3330 for Diabetic Retinopathy at Two Scientific Meetings in July(Globenewswire)
2024-06-05 19:57
Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy at Retina Meetings in June(Globenewswire)
2024-05-10 01:53
OCUP Stock Earnings: Ocuphire Pharma Misses EPS, Misses Revenue for Q1 2024(Investorplace)
2024-05-09 20:00
Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update(Globenewswire)
2024-05-05 20:00
Ocuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual Meeting(Globenewswire)
2024-05-02 20:00
Ocuphire Pharma to Present at the Aegis Virtual Conference(Globenewswire)
2024-04-21 20:00
Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting(Globenewswire)
2024-04-10 22:03
First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery(Globenewswire)
2024-03-31 19:14
Ocuphire Announces the U.S. Commercial Launch of RYZUMVl (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris(Globenewswire)
2024-03-14 23:53
OCUP Stock Earnings: Ocuphire Pharma Misses EPS, Misses Revenue for Q4 2023(Investorplace)
2024-03-09 00:09
12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds(Insidermonkey)
2024-03-07 19:00
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update(Globenewswire)
2024-03-03 19:18
Ocuphire (OCUP) to Report Q4 Earnings: What's in the Cards?(Zacks)
2024-02-22 19:00
Ocuphire Pharma to Present in the BIO CEO & Investor Conference(Globenewswire)
2024-02-15 03:10
Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-02-13 19:00
Ocuphire Pharma Strengthens Leadership Team with Key Appointments(Globenewswire)
2024-02-04 19:00
Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference(Globenewswire)
2024-01-24 03:10
Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-01-10 18:41
Here's Why You Should Invest in Ocuphire Pharma (OCUP) Now(Zacks)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.